Slingshot members are tracking this event:
CymaBay(CBAY) Halts Clinical Development of Seladelpar
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
The decision to halt development of seladelpar was based on initial histological findings observed in the Phase 2b study of seladelpar in NASH. Planned, blinded histological assessments of the first tranche of liver biopsies in the trial revealed atypical histological findings, including histology characterized as an interface hepatitis presentation, with or without biliary injury. The company has initiated a series of investigative actions to better understand these findings.
Slingshot Insights Explained
Nov 25, 2019
Don’t see a project related to the catalyst you care about?
Related Keywords Seladelpar, Non-alcoholic Steatohepatitis, Discontinuation